CEL-SCI and Saudi Amarox to Habits Signing Rite at BIO 2026 for Strategic Settlement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

Saudi Arabia Emerges as a International Biotech Funding Hub Underneath Imaginative and prescient 2030

Senior Saudi Executive, Funding and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies

Strategic Settlement Marks Vital Step Towards Commercialization of Multikine ® in One of the crucial Center East’s Quickest-Rising Healthcare Markets

CEL-SCI Company (NYSE American: CVM) these days introduced it’ll take part in a proper signing rite with Saudi Amarox (” Amarox “) all over the BIO Global Conference 2026 in San Diego, California. The rite will mark crucial milestone in advancing the prior to now introduced strategic settlement between the corporations centered at the commercialization and distribution of Multikine ®* (Leukocyte Interleukin, Injection) within the Kingdom of Saudi Arabia.

The BIO Global Conference, the arena’s greatest biotechnology trade match, will happen June 22-25, 2026, bringing in combination biotechnology, pharmaceutical, funding and executive leaders from around the globe.

The authentic signing rite will happen all over the outlet rite of the Saudi Amarox sales space on Monday, June 22, 2026, from 12:00 PM to at least one:00 PM PST. CEL-SCI’s Leader Government Officer Geert Kersten and representatives from Amarox will take part within the rite, officially spotting the corporations’ collaboration on bringing Multikine to sufferers in Saudi Arabia.

The development comes as Saudi Arabia speeds up its emergence as an international chief in biotechnology and existence sciences investments below the Kingdom’s Imaginative and prescient 2030 technique. The Saudi Ministry of Well being is an authentic sponsor of BIO 2026 and has established biotechnology as a strategic precedence, with important private and non-private funding.

“Saudi Arabia is making substantial investments to build one of the world’s most dynamic biotechnology sectors, creating significant opportunities for innovative therapies such as Multikine,” mentioned Geert Kersten, Leader Government Officer of CEL-SCI. “Our collaboration with Amarox represents an important step toward making Multikine available to patients in Saudi Arabia, establishing a foundation for long-term growth throughout the region. We are honored to participate in these events alongside key government, healthcare and investment leaders who are helping shape the future of biotechnology in the Kingdom.”

Saudi Arabia’s increasing prominence in biotechnology may also be highlighted all over BIO 2026 during the featured consultation , “From Vision to Value: Private-Led Biotech Market Growth Powered by Saudi Arabia’s Agile Ecosystem.” One in every of featured audio system is Abdulaziz Al-Qahtani, PharmD, Pipeline & Marketplace Get entry to Director at Amarox, underscoring Amarox’s function in advancing Saudi Arabia’s existence sciences ambitions.

The signing rite follows the strategic settlement prior to now introduced by means of CEL-SCI and Amarox to collaborate on regulatory, commercialization and distribution actions for Multikine in Saudi Arabia. The phrases of the settlement come with a 50%/50% income proportion for Multikine gross sales in Saudi Arabia upon receipt of Step forward Medication Designation. Amarox, ranked #1 for Saudi-FDA (SFDA) programs for crucial and unavailable medication for three consecutive years, will act because the native regulatory consultant and lead all communications with the SFDA. Along with being the unique industrial distributor of Multikine in Saudi Arabia, upon SFDA approval, Amarox has the approach to make bigger the settlement into the Gulf Cooperation Council (GCC) nations together with Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates. Immunotherapy is one of the fastest-growing segments within the Saudi most cancers marketplace, projected to achieve $2.7 billion by means of 2033.

About Multikine

Multikine is a most cancers immunotherapy administered sooner than surgical procedure as a remedy for newly identified prior to now untreated head and neck most cancers. Its function is to turn on an individual’s immune machine to struggle most cancers sooner than the ravages of surgical procedure, radiation and chemotherapy have weakened the immune machine. On this planet’s greatest head and neck most cancers Segment 3 learn about, Multikine greater the 5-year survival fee of the objective affected person inhabitants to 73% vs 45% in sufferers handled with usual of care by myself and halved the chance of loss of life from 55% to 27%.

About Head and Neck Most cancers

Head and neck most cancers is the 6 th maximum not unusual most cancers, with roughly 900,000 newly identified instances in keeping with 12 months globally. The newly identified level 3 and four sufferers with this most cancers constitute a serious unmet want.

About Cel-Sci Company

CEL-SCI believes that boosting a affected person’s immune machine sooner than surgical procedure, radiotherapy and chemotherapy have broken it, will have to give you the biggest conceivable affect on survival. Multikine is designed to assist the immune machine “target” the tumor at a time when the immune machine remains to be somewhat intact and thereby regarded as higher in a position to mount an assault at the tumor.

Multikine (Leukocyte Interleukin, Injection), given proper after prognosis and sooner than surgical procedure, has been dosed in over 740 sufferers and gained Orphan Drug designation from the FDA for neoadjuvant treatment in sufferers with squamous cellular carcinoma (most cancers) of the pinnacle and neck.

The Corporate has operations in Vienna, Virginia, and close to/in Baltimore, Maryland.

Ahead-Taking a look Statements

This press liberate accommodates forward-looking statements inside the which means of Segment 27A of the Securities Act of 1933, as amended, and Segment 21E of the Securities Change Act of 1934, as amended. When used on this press liberate, the phrases “intends,” “believes,” “anticipated,” “plans” and “expects,” and identical expressions, are meant to spot forward-looking statements. Such statements are matter to dangers and uncertainties that would motive exact effects to range materially from the ones projected. Components that would motive or give a contribution to such variations come with an incapability to replicate the medical effects demonstrated in medical research, well timed construction of any possible merchandise that may be proven to be protected and efficient, receiving essential regulatory approvals, difficulties in production any of the Corporate’s possible merchandise, incapability to lift the essential capital, incapability to finalize a partnering settlement and the chance elements set forth once in a while in CEL-SCI’s filings with the Securities and Change Fee, together with however no longer restricted to its document on Shape 10-Okay for the 12 months ended September 30, 2025. The Corporate undertakes no legal responsibility to publicly liberate the results of any revision to those forward-looking statements that could be made to mirror the occasions or instances after the date hereof or to mirror the prevalence of unanticipated occasions.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational treatment. This proprietary identify is matter to FDA evaluation in reference to the Corporate’s long term expected regulatory submission for approval. Multikine has no longer been authorized or licensed on the market, barter or change by means of the FDA or every other regulatory company. In a similar fashion, its protection or efficacy has no longer been established for any use.